Fate Therapeutics Inc (NASDAQ: FATE) |
|
Overall company Market Share Q1 2025 |
*Market share is calculated based on total revenue.
News about Fate Therapeutics Inc Contracts |
November 8, 2024
Cutting-Edge CAR T-Cell Therapy: Fate Therapeutics? Breakthrough Data and Stellar Financial Performance Set to Revolutionize Cancer TreatmentIn an era where advancements in immunotherapy are reshaping oncological treatment paradigms, Fate Therapeutics, Inc. has emerged as a frontrunner with the presentation of its preclinical data for its innovative FT836 product candidate. Highlighted at the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC), FT836 represents a cutting-edge leap in the realm of CAR T-cell therapies. This multiplexed-engineered, induced pluripotent stem cell (iPSC)-derived CAR T-cell product targets specific proteins expressed on cancer cells that are both a product of ce...
|
May 9, 2024
Fate Therapeutics, a leading biopharmaceutical company focused on the development of off-the-shelf cell therapies, recently announced significant advancements in their groundbreaking CAR T-cell programs for the treatment of autoimmune disorders and advanced solid tumors. The company has successfully treated the first Lupus patient in their Phase 1 Autoimmunity Study using the FT819 CAR T-cell program, while also initiating a Phase 1 Clinical Trial for the HER2-expressing advanced solid tumors treatment with FT825/ONO-8250 iPSC-derived CAR T-cell product candidate.In the Phase 1 Autoimmunity Study, Fate Therapeutics demonstrated the efficacy of their off-the-shelf FT819 CAR T-cell program in the treatment of ...
|
January 8, 2024
San Diego-based biopharmaceutical company Fate Therapeutics, in conjunction with Ono Pharmaceutical Co., recently announced the initiation of a groundbreaking Phase 1 Clinical Trial for cellular immunotherapy FT825/ONO-8250 in patients battling HER2-expressing advanced solid tumors. Encompassing a novel HER2-targeted antigen-binding domain, this innovative product candidate originates from induced pluripotent stem cells (iPSCs).Fate Therapeutics, notable for its transformative work in cell-based cancer immunotherapy, is incorporating an unprecedented seven synthetic controls of cell function into FT825/ONO-8250 in its pursuit of pioneering novel treatments. HER2 (human epidermal growth factor receptor 2) is ...
|
Publicly Traded Peers of Fate Therapeutics Inc
Adicet Bio Inc Share Performance
-9.14%
Over The Past 5 Days
|
Adicet Bio Inc
Profile
Adicet Bio Inc's business model involves the development and commercialization of cell therapy medications for various diseases.
More about Adicet Bio Inc 's Market Share
|
Adaptimmune Therapeutics Plc Share Performance
-53.82%
This Quarter
|
Adaptimmune Therapeutics Plc
Profile
Adaptimmune Therapeutics Plc is a biopharmaceutical company that focuses on developing and commercializing innovative cancer immunotherapy products. Their business model revolves around leveraging their T-cell receptor platform to engineer and develop targeted immunotherapies for patients with various types of cancer.
More about Adaptimmune Therapeutics Plc's Market Share
|
Vincerx Pharma Inc Share Performance
-95.60%
This Quarter
|
Vincerx Pharma Inc
Profile
Vincerx Pharma Inc's business model is focused on developing and commercializing novel small molecule drugs for the treatment of cancer. They aim to leverage their scientific expertise and collaborations to identify and advance promising drug candidates, ultimately providing innovative therapies to patients in need.
More about Vincerx Pharma Inc 's Market Share
|
Verastem Inc Share Performance
+9.18%
30 Days
|
Verastem Inc
Profile
Verastem Inc is a biopharmaceutical company that focuses on discovering and developing medicines to treat cancer by targeting the underlying biology of the disease. They employ a research-driven business model to identify novel therapeutic candidates, evaluate their potential through preclinical and clinical trials, and bring them to market with the goal of improving patient outcomes. Verastem emphasizes innovation, precision medicine, and strategic collaborations to advance their pipeline of cancer therapeutics.
More about Verastem Inc 's Market Share
|
Bellicum Pharmaceuticals Inc Share Performance
-65.67%
This Quarter
|
Bellicum Pharmaceuticals Inc
Profile
Bellicum Pharmaceuticals Inc's business model is focused on the development and commercialization of innovative cellular immunotherapies for the treatment of cancers and other serious diseases.
More about Bellicum Pharmaceuticals Inc 's Market Share
|
Oncosec Medical Incorporated Share Performance
-85.64%
This Quarter
|
Oncosec Medical Incorporated
Profile
Oncosec Medical Incorporated's business model revolves around developing and commercializing innovative immunotherapies for the treatment of various cancers.
More about Oncosec Medical Incorporated's Market Share
|
Oncorus Inc Share Performance
-54.69%
This Year
|
Oncorus Inc
Profile
Oncorus Inc is a biotechnology company that specializes in developing next-generation viral immunotherapies to treat various types of cancers. Their business model revolves around leveraging the power of oncolytic viruses, which selectively target and destroy cancer cells while stimulating an immune response against the tumor. Oncorus focuses on rigorous research, clinical development, and potential partnerships to advance their innovative therapies towards commercialization and widespread patient access.
More about Oncorus Inc 's Market Share
|
Athersys Inc Share Performance
-98.76%
One Year
|
Athersys Inc
Profile
Athersys Inc's business model revolves around the development and commercialization of novel cellular therapeutics.
More about Athersys Inc's Market Share
|
Tcr2 Therapeutics Inc Share Performance
+58.00%
This Year
|
Tcr2 Therapeutics Inc
Profile
TCR2 Therapeutics Inc is a biotechnology company that focuses on the development of innovative immunotherapies for cancer treatment. Their business model entails leveraging their proprietary T-cell receptor (TCR) Fusion Construct T cells platform to create therapies that effectively target and eliminate cancer cells.
More about Tcr2 Therapeutics Inc 's Market Share
|
Pmv Pharmaceuticals Inc Share Performance
-41.17%
This Year
|
Pmv Pharmaceuticals Inc
Profile
Pmv Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing precision therapies for cancer patients. They employ a collaborative business model that combines deep scientific expertise, strategic partnerships, and advanced technology to identify and target specific genetic alterations in cancer cells. By leveraging these insights, Pmv Pharmaceuticals aims to create innovative treatments that can improve patient outcomes and address unmet medical needs in oncology.
More about Pmv Pharmaceuticals Inc 's Market Share
|
Celularity Inc Share Performance
+58.78%
30 Days
|
Celularity Inc
Profile
Celularity is a biotechnology company that focuses on developing and delivering transformative cellular therapies for various diseases. Their business model encompasses acquiring and licensing cellular assets, conducting research and development to advance these therapies, and forming strategic partnerships with healthcare organizations and research institutions to commercialize and distribute their innovative products. Through this model, Celularity aims to address unmet medical needs and provide novel therapies to improve patient outcomes.
More about Celularity Inc 's Market Share
|
Geron Corp Share Performance
-17.82%
This Quarter
|
Geron Corp
Profile
Geron Corp is a biopharmaceutical company that focuses on the discovery and development of therapeutic products for the treatment of cancer and chronic degenerative diseases. Their business model is based on researching and identifying innovative drug candidates, conducting preclinical and clinical trials to evaluate their safety and efficacy, and ultimately partnering with larger pharmaceutical companies for late-stage clinical development and commercialization. Geron Corp aims to leverage their scientific expertise and strategic collaborations to bring novel therapies to market and improve patient outcomes.
More about Geron Corp's Market Share
|
Atreca inc Share Performance
-31.14%
This Year
|
Atreca inc
Profile
Atreca Inc operates on a unique business model focused on developing novel therapeutics by leveraging its proprietary Immune Repertoire Capture (IRC) technology to analyze and identify antibodies present in patients with specific diseases, ultimately enabling the development of targeted therapies.
More about Atreca inc 's Market Share
|
Cabaletta Bio Inc Share Performance
-1.06%
This Quarter
|
Cabaletta Bio Inc
Profile
Cabaletta Bio Inc's business model revolves around developing and commercializing genetically engineered T cell therapies for the treatment of autoimmune diseases. They aim to utilize their proprietary technology platform to engineer Chimeric AutoAntibody Receptor (CAAR) T cells, which are designed to selectively target and eliminate disease-causing B cells. By focusing on autoimmune diseases with high unmet medical needs, Cabaletta Bio Inc aims to provide effective and personalized therapeutic solutions to patients.
More about Cabaletta Bio Inc 's Market Share
|
Bluebird Bio Inc Share Performance
-42.69%
This Year
|
Bluebird Bio Inc
Profile
Bluebird Bio Inc's business model focuses on developing gene therapies for severe genetic diseases and cancer. They collaborate with academic and industry partners to leverage their gene editing and cell-based technologies for discovering potential treatments and advancing these therapies through clinical trials.
More about Bluebird Bio Inc 's Market Share
|
Bristol myers Squibb Company Share Performance
-16.48%
This Year
|
Bristol myers Squibb Company
Profile
Bristol Myers Squibb Company operates a research and development-driven business model, focusing on the discovery and delivery of innovative medicines for various diseases. It emphasizes collaboration with academic institutions, government entities, and other pharmaceutical firms to enhance its therapeutic portfolio and improve patient outcomes.
More about Bristol myers Squibb Company's Market Share
|
Allogene Therapeutics Inc Share Performance
-25.97%
30 Days
|
Allogene Therapeutics Inc
Profile
Allogene Therapeutics Inc has a business model that focuses on developing and commercializing innovative allogeneic CAR T cell therapies for the treatment of cancer.
More about Allogene Therapeutics Inc 's Market Share
|
Cell Source Inc Share Performance
0.00%
30 Days
|
Cell Source Inc
Profile
Cell Source Inc is a biotechnology company that specializes in the development and commercialization of innovative treatments for diseases. Their business model focuses on leveraging advanced cell therapy technologies to create personalized and regenerative therapies for patients. By partnering with research institutions and healthcare organizations, Cell Source aims to bring their cutting-edge solutions to the market, ultimately improving health outcomes and patient quality of life.
More about Cell Source Inc 's Market Share
|
Maia Biotechnology Inc Share Performance
-58.54%
One Year
|
Maia Biotechnology Inc
Profile
Maia Biotechnology Inc is a biotechnology company that focuses on developing innovative therapies for cancer treatment. Their business model revolves around leveraging advanced genomic technologies to identify novel targets for drug development. By combining their expertise in genomics and drug discovery, they aim to create personalized and targeted therapies to improve patient outcomes in the field of oncology.
More about Maia Biotechnology Inc 's Market Share
|
Carisma Therapeutics Inc Share Performance
-55.56%
This Year
|
Carisma Therapeutics Inc
Profile
Carisma Therapeutics Inc's business model focuses on developing novel CAR-Macrophage cell therapies to treat solid tumors. They aim to leverage their proprietary technology platform to engineer immune cells that can effectively target and destroy cancer cells, while also optimizing the manufacturing process for scalability and cost-effectiveness.
More about Carisma Therapeutics Inc 's Market Share
|
Enlivex Therapeutics Ltd Share Performance
-23.39%
This Year
|
Enlivex Therapeutics Ltd
Profile
Enlivex Therapeutics Ltd's business model focuses on developing and commercializing novel immune system therapies.
More about Enlivex Therapeutics Ltd 's Market Share
|
Marker Therapeutics inc Share Performance
-24.83%
This Quarter
|
Marker Therapeutics inc
Profile
Marker Therapeutics Inc is a biotechnology company that aims to develop and commercialize novel T cell immunotherapies for the treatment of cancer. Their business model focuses on leveraging their expertise in cellular engineering to develop proprietary technologies and therapies that can be licensed or partnered with other organizations for further development and commercialization.
More about Marker Therapeutics inc 's Market Share
|
Merus N v Share Performance
-1.60%
Over The Past 5 Days
|
Merus N v
Profile
Merus N V is a biotechnology company that operates using a differentiated and competitive business model. Their approach involves strategically targeting and developing bispecific antibodies to treat various types of cancer, leveraging their proprietary technologies and expertise in the field. By focusing on innovative research, efficient drug discovery, and partnerships, they aim to improve patient outcomes and drive growth in the oncology market.
More about Merus N v 's Market Share
|
Autolus Therapeutics Plc Share Performance
+25.95%
30 Days
|
Autolus Therapeutics Plc
Profile
Autolus Therapeutics Plc is a biopharmaceutical company that focuses on the development and commercialization of next-generation engineered T-cell therapies for the treatment of cancer. Their business model is centered around utilizing innovative technology and expertise to create and advance novel therapies aimed at improving patient outcomes in oncology.
More about Autolus Therapeutics Plc's Market Share
|
Surface Oncology Inc Share Performance
0.00%
Over The Past 5 Days
|
Surface Oncology Inc
Profile
Surface Oncology Inc is a biotechnology company focused on developing innovative immunotherapies to treat cancer. They employ a research-driven approach to identify and target novel immune checkpoints and design therapeutic antibodies to activate the immune system against tumors. Their business model revolves around conducting preclinical and clinical research, collaborating with strategic partners, and licensing or commercializing their products to bring new treatment options to patients.
More about Surface Oncology Inc 's Market Share
|
Agenus Inc Share Performance
-20.32%
Over The Past 5 Days
|
Agenus Inc
Profile
Agenus Inc is a biotechnology company that primarily focuses on the discovery and development of immune-based therapies for cancer treatment. Their business model revolves around leveraging their proprietary technologies and capabilities to develop and commercialize therapeutic antibodies and vaccines. Agenus Inc also collaborates with other pharmaceutical companies through licensing agreements and partnerships to further advance their product pipeline.
More about Agenus Inc's Market Share
|
Poseida Therapeutics Inc Share Performance
+1.06%
This Year
|
Poseida Therapeutics Inc
Profile
Poseida Therapeutics Inc's business model revolves around developing and commercializing gene therapies for a wide range of diseases and conditions.
More about Poseida Therapeutics Inc 's Market Share
|
Gilead Sciences Inc Share Performance
+72.94%
One Year
|
Gilead Sciences Inc
Profile
Gilead Sciences Incs business model centers on researching, developing, and marketing innovative medicines, primarily targeting antiviral therapies. They focus on addressing unmet medical needs to enhance patient health globally.
More about Gilead Sciences Inc 's Market Share
|
Moderna Inc Share Performance
-82.26%
One Year
|
Moderna Inc
Profile
Moderna Inc's business model revolves around the development and commercialization of mRNA-based therapeutics and vaccines. They focus on using messenger RNA (mRNA) technology to create drugs that can help prevent and treat various diseases.
More about Moderna Inc 's Market Share
|
Amgen Inc Share Performance
-7.86%
This Quarter
|
Amgen Inc
Profile
Amgen Inc.s business model focuses on leveraging advanced biotechnology to create therapeutic products for various diseases, particularly in the fields of oncology, inflammation, and cardiovascular health. The company invests heavily in research and development to drive innovation, while also utilizing strategic partnerships and acquisitions to enhance its product pipeline. Additionally, Amgen emphasizes a strong global commercial presence to maximize the accessibility and impact of its therapeutics in the healthcare market.
More about Amgen Inc 's Market Share
|
Zeo Scientifix Inc Share Performance
-61.04%
This Year
|
Zeo Scientifix Inc
Profile
Organicell Regenerative Medicine Inc's business model focuses on developing and commercializing regenerative therapies derived from perinatal tissues, such as placental tissues and umbilical cord blood.
More about Zeo Scientifix Inc 's Market Share
|
Peak Bio Inc Share Performance
0.00%
30 Days
|
Peak Bio Inc
Profile
Peak Bio Inc is a biotechnology company specializing in the development and commercialization of innovative medical products. Their business model focuses on conducting extensive research and development to create cutting-edge biopharmaceuticals. These products are then marketed and distributed to healthcare providers and patients, aiming to improve patient outcomes and contribute to advancements in the healthcare industry.
More about Peak Bio Inc 's Market Share
|
Tracon Pharmaceuticals Inc Share Performance
-29.07%
30 Days
|
Tracon Pharmaceuticals Inc
Profile
Tracon Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing targeted therapies for cancer and ocular diseases. They primarily collaborate with strategic partners to advance their drug candidates through clinical trials and potentially secure regulatory approval.
More about Tracon Pharmaceuticals Inc 's Market Share
|
Brainstorm Cell Therapeutics inc Share Performance
-86.64%
One Year
|
Brainstorm Cell Therapeutics inc
Profile
Brainstorm Cell Therapeutics Inc's business model is centered around developing and commercializing innovative adult stem cell therapies for neurodegenerative diseases.
More about Brainstorm Cell Therapeutics inc 's Market Share
|
Gamida Cell Ltd Share Performance
-90.31%
This Quarter
|
Gamida Cell Ltd
Profile
Gamida Cell Ltd's business model is focused on developing and bringing innovative cell therapies to market for the treatment of various diseases, with a particular emphasis on hematological malignancies and serious blood disorders.
More about Gamida Cell Ltd 's Market Share
|
Avalon Globocare Corp Share Performance
-14.30%
One Year
|
Avalon Globocare Corp
Profile
Avalon Globocare Corp's business model is focused on providing innovative healthcare solutions and services through strategic acquisitions, partnerships, and collaborations in the biotechnology and healthcare sectors.
More about Avalon Globocare Corp's Market Share
|
Atara Biotherapeutics Inc Share Performance
+9.70%
Over The Past 5 Days
|
Atara Biotherapeutics Inc
Profile
Atara Biotherapeutics Inc is a biotechnology company that focuses on developing therapies for patients with serious medical conditions. They utilize a personalized medicine approach to create off-the-shelf, allogeneic T-cell immunotherapies. By leveraging their expertise in T-cell immunotherapy and genetic engineering, they aim to provide innovative treatments with the potential for broad patient reach.
More about Atara Biotherapeutics Inc 's Market Share
|
Senti Biosciences Inc Share Performance
-1.56%
Over The Past 5 Days
|
Senti Biosciences Inc
Profile
Senti Biosciences Inc is a biotechnology company that develops and commercializes novel therapeutics using synthetic biology and gene editing technology.
More about Senti Biosciences Inc 's Market Share
|
Biocardia Inc Share Performance
-30.82%
30 Days
|
Biocardia Inc
Profile
Biocardia Inc's business model involves developing and commercializing innovative medical therapies and devices to treat cardiovascular diseases.
More about Biocardia Inc's Market Share
|
Kiromic Biopharma Inc Share Performance
-85.18%
Over The Past 5 Days
|
Kiromic Biopharma Inc
Profile
Kiromic Biopharma Inc is a biotechnology company that focuses on developing targeted immunotherapies for the treatment of cancer. Their business model revolves around utilizing their proprietary technology platforms to identify tumor-specific antigens and develop personalized therapies to effectively target and eliminate cancer cells.
More about Kiromic Biopharma Inc 's Market Share
|
Coeptis Therapeutics Holdings Inc Share Performance
+53.30%
This Year
|
Coeptis Therapeutics Holdings Inc
Profile
Coeptis Therapeutics Holdings Inc. is a pharmaceutical company that focuses on the development and commercialization of innovative therapies. Their business model involves researching, formulating, and manufacturing drugs to address unmet medical needs in various therapeutic areas. They aim to bring these treatments to market to improve patient outcomes and generate revenue through sales and licensing agreements.
More about Coeptis Therapeutics Holdings Inc 's Market Share
|
Organovo Holdings Inc Share Performance
-52.43%
This Quarter
|
Organovo Holdings Inc
Profile
Organovo Holdings Inc is a biotechnology company that specializes in creating functional 3D human tissue models for medical research and therapeutic purposes. They use a combination of 3D bioprinting and other innovative technologies to produce highly precise and realistic tissue constructs. These models are utilized by pharmaceutical companies to accelerate the drug discovery process and potentially reduce the need for animal testing.
More about Organovo Holdings Inc 's Market Share
|
Compass Therapeutics Inc Share Performance
0.00%
Over The Past 5 Days
|
Compass Therapeutics Inc
Profile
Compass Therapeutics Inc operates as a biotechnology company focused on discovering and developing novel antibody therapeutics for the treatment of cancer and autoimmune diseases. Their business model revolves around leveraging their proprietary Targeted Immunomodulation platform to identify and advance multiple antibody candidates through preclinical and clinical development stages.
More about Compass Therapeutics Inc 's Market Share
|
Gritstone Bio Inc Share Performance
-98.52%
This Year
|
Gritstone Bio Inc
Profile
Gritstone Bio Inc is a biotechnology company that focuses on developing personalized cancer immunotherapies. Their business model revolves around utilizing their proprietary genomics platform to identify patient-specific tumor targets and developing therapies that stimulate the immune system to recognize and attack cancer cells.
More about Gritstone Bio Inc 's Market Share
|
Turnstone Biologics Corp Share Performance
-7.92%
This Quarter
|
Turnstone Biologics Corp
Profile
Turnstone Biologics Corp is a biotechnology company that focuses on developing innovative cancer treatments. Their business model includes leveraging their proprietary vaccinia virus-based platform to engineer oncolytic viral immunotherapies. These therapies are designed to selectively target and destroy cancer cells while also activating the patient's immune system to generate a lasting anti-tumor response.
More about Turnstone Biologics Corp 's Market Share
|
Humacyte Inc Share Performance
-45.37%
This Year
|
Humacyte Inc
Profile
Humacyte Inc is a biotechnology company that focuses on creating bioengineered human tissue constructs for numerous medical applications. Their business model revolves around developing and commercializing their proprietary Humacyl platform, which uses a patient's own cells to create acellular scaffolds that mimic human tissue. These tissue constructs can be used for various purposes such as vascular replacements, functional tissues, and potential regenerative medicine therapies.
More about Humacyte Inc 's Market Share
|
Nkgen Biotech Inc Share Performance
+96.29%
30 Days
|
Nkgen Biotech Inc
Profile
Nkgen Biotech Inc is a biotechnology company that focuses on developing and commercializing innovative cell therapies for the treatment of various diseases. Their business model involves conducting extensive research to identify and isolate specific cells capable of addressing medical conditions, followed by developing manufacturing processes to produce these cells in large quantities. They aim to partner with healthcare providers and pharmaceutical companies to ensure the effective distribution and delivery of their therapies to patients in need.
More about Nkgen Biotech Inc 's Market Share
|
Century Therapeutics inc Share Performance
-46.15%
This Year
|
Century Therapeutics inc
Profile
Century Therapeutics Inc. is a biotechnology company that aims to develop novel cell therapies targeting various diseases. Their business model focuses on leveraging induced pluripotent stem cell (iPSC) technology to engineer cellular therapies and bring them to market, with a specific emphasis on treating cancer.
More about Century Therapeutics inc 's Market Share
|
Armata Pharmaceuticals Inc Share Performance
+35.94%
30 Days
|
Armata Pharmaceuticals Inc
Profile
Armata Pharmaceuticals Inc operates on a research and development business model focused on discovering and developing bacteriophage-based therapies to combat antibiotic-resistant infections. They utilize their proprietary phage technology platform to create novel pharmaceutical products targeting various bacterial diseases.
More about Armata Pharmaceuticals Inc 's Market Share
|
Molecular Partners Ag Share Performance
-11.45%
Over The Past 5 Days
|
Molecular Partners Ag
Profile
Molecular Partners Ag is a biotechnology company that operates on an innovative business model focused on the development of therapeutic drugs. The company utilizes its proprietary DARPin technology platform to create a pipeline of potential treatments for various diseases. Molecular Partners Ag primarily collaborates with strategic partners, including pharmaceutical companies, to advance its drug candidates through preclinical and clinical development stages.
More about Molecular Partners Ag's Market Share
|
Sutro Biopharma Inc Share Performance
-78.45%
One Year
|
Sutro Biopharma Inc
Profile
Sutro Biopharma Inc has a business model focused on developing and commercializing innovative antibody-based therapeutics.
More about Sutro Biopharma Inc 's Market Share
|
Genenta Science S p a Share Performance
-1.99%
This Year
|
Genenta Science S p a
Profile
Genenta Science S.p.A. operates on a business model focused on the development of immuno-gene therapies for the treatment of cancer. They aim to leverage their proprietary technology to genetically modify autologous hematopoietic stem cells and engineer them to express immunomodulatory protein IL-12. These modified cells are then reinfused into patients to stimulate an immune response against tumors, potentially offering a novel and personalized approach to cancer treatment.
More about Genenta Science S p a 's Market Share
|
Tscan Therapeutics Inc Share Performance
-8.81%
30 Days
|
Tscan Therapeutics Inc
Profile
Tscan Therapeutics Inc is a biotechnology company that focuses on developing and commercializing T cell receptor therapies for cancer patients. Their business model revolves around leveraging their T cell platform to develop innovative treatments and secure partnerships with other pharmaceutical companies for clinical development and commercialization.
More about Tscan Therapeutics Inc 's Market Share
|
Meiragtx Holdings Plc Share Performance
-24.96%
30 Days
|
Meiragtx Holdings Plc
Profile
MeiraGTx Holdings Plc is a biotechnology company focused on developing gene therapies for inherited and acquired diseases. They leverage their proprietary technology to develop and commercialize innovative treatments that address unmet medical needs.
More about Meiragtx Holdings Plc's Market Share
|
Instil Bio Inc Share Performance
+33.75%
This Quarter
|
Instil Bio Inc
Profile
Instil Bio Inc operates with a business model focusing on developing and commercializing innovative cell therapy products for the treatment of cancer. They aim to leverage advanced technologies and strategic partnerships to advance their pipeline and bring novel therapies to market.
More about Instil Bio Inc 's Market Share
|
Iovance Biotherapeutics inc Share Performance
0.00%
Over The Past 5 Days
|
Iovance Biotherapeutics inc
Profile
Iovance Biotherapeutics Inc operates on a business model centered around developing and commercializing novel cancer immunotherapy treatments. The company focuses on utilizing its proprietary Tumor Infiltrating Lymphocyte (TIL) therapy, which involves collecting and expanding a patient's own immune cells to target and kill cancer cells. Iovance primarily seeks to advance its TIL therapy candidates through clinical trials and collaborations while aiming to provide effective and personalized treatment options for cancer patients.
More about Iovance Biotherapeutics inc 's Market Share
|
Replimune Group Inc Share Performance
-36.33%
This Quarter
|
Replimune Group Inc
Profile
Replimune Group Inc has a business model centered around the development of oncolytic immunotherapies.
More about Replimune Group Inc 's Market Share
|
Aura Biosciences Inc Share Performance
-20.00%
This Quarter
|
Aura Biosciences Inc
Profile
Aura Biosciences Inc is a biotechnology company that focuses on developing and commercializing therapies to treat cancer. They utilize their proprietary Tumor Paint technology to selectively deliver light-activated drugs directly to tumors, aiming to improve treatment outcomes and minimize side effects.
More about Aura Biosciences Inc 's Market Share
|
Ambrx Biopharma Inc Share Performance
+0.21%
Over The Past 5 Days
|
Ambrx Biopharma Inc
Profile
Ambrx Biopharma Inc's business model can be described as a biopharmaceutical company that focuses on developing protein therapeutics through the use of its proprietary technology called ReCODE?.
More about Ambrx Biopharma Inc 's Market Share
|
Lexeo Therapeutics Inc Share Performance
-23.25%
30 Days
|
Lexeo Therapeutics Inc
Profile
Lexeo Therapeutics Inc is a biotechnology company focused on developing advanced gene therapies for the treatment of genetic disorders. Their business model revolves around leveraging cutting-edge technology and scientific expertise to develop innovative gene therapies that address significant unmet medical needs. They aim to bring these therapies to market through strategic partnerships and collaborations with pharmaceutical companies and academic institutions.
More about Lexeo Therapeutics Inc 's Market Share
|
Revolution Medicines Inc Share Performance
-14.25%
This Year
|
Revolution Medicines Inc
Profile
Revolution Medicines Inc operates as a biopharmaceutical company that focuses on discovering and developing new drugs to target cancers and other diseases caused by defects in cellular signaling. Their business model involves leveraging their expertise in precision oncology and molecular biology to identify novel drug candidates and advance them through preclinical and clinical development stages.
More about Revolution Medicines Inc 's Market Share
|
Immunitybio inc Share Performance
+3.56%
Over The Past 5 Days
|
Immunitybio inc
Profile
Immunitybio Inc operates on a business model that focuses on developing and commercializing innovative immunotherapies and vaccines to address various diseases and medical conditions. They aim to use their broad scientific expertise, technology platforms, and strategic partnerships to advance their products and improve patient outcomes in healthcare.
More about Immunitybio inc 's Market Share
|
Immix Biopharma Inc Share Performance
-19.09%
Over The Past 5 Days
|
Immix Biopharma Inc
Profile
ImmIx Biopharma Inc is a biotechnology company that focuses on developing novel therapeutics for the treatment of cancer. Their business model involves conducting extensive research and development to discover and optimize drug candidates, followed by preclinical and clinical testing to assess their safety and effectiveness. They aim to collaborate with pharmaceutical companies or seek licensing agreements to further develop and commercialize their biopharmaceutical products.
More about Immix Biopharma Inc 's Market Share
|
Neximmune Inc Share Performance
0.00%
This Quarter
|
Neximmune Inc
Profile
Neximmune Inc is a biotechnology company that focuses on developing personalized immunotherapies to treat various cancers and autoimmune diseases.
More about Neximmune Inc 's Market Share
|
Sources: Fate Therapeutics Inc and all companies mentioned above in this report
|